AOP Health Wins FDA Approval for Rapiblyk in Pediatric SVT

Wilmington, Delaware, U.S. | April 15, 2026

AOP Health US, LLC has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approval of RAPIBLYK® (landiolol) for the treatment of pediatric patients with supraventricular tachycardia (SVT). This approval expands the drug’s indication beyond adults to include patients from birth to under 18 years of age, making it the first approved therapeutic option for pediatric SVT in the United States. The decision underscores the growing importance of targeted cardiovascular therapies in critical care settings and highlights AOP Health’s commitment to addressing unmet medical needs in pediatric cardiology.

FDA Approval Expands Treatment Options in Pediatric Cardiology

The FDA approval of RAPIBLYK® for pediatric use marks a critical advancement in the management of supraventricular tachycardia, a condition characterized by abnormally rapid heart rhythms that can require immediate intervention in acute care environments. Until now, treatment options specifically approved for pediatric patients have been limited, creating challenges for clinicians managing these cases.

RAPIBLYK’s approval provides healthcare professionals with a validated, evidence-based therapy designed for precise and controlled heart rate reduction, improving treatment outcomes in high-risk pediatric populations. This milestone reflects the importance of regulatory progress in expanding access to life-saving therapies across all age groups, particularly in conditions requiring rapid clinical response.

Clinical Evidence Supports Efficacy and Safety Profile

The FDA’s decision is supported by results from the LANDI-PED clinical study, which evaluated RAPIBLYK in pediatric patients with SVT. The study demonstrated a clinically meaningful reduction of over 20% in ventricular rate from baseline, confirming the drug’s effectiveness in controlling abnormal heart rhythms. RAPIBLYK is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously, offering rapid onset and offset of action.

This pharmacological profile enables clinicians to quickly adjust dosing and achieve precise heart rate control, which is critical in emergency and critical care settings. Additionally, the therapy’s favorable hemodynamic profile supports its safe use in vulnerable patient populations, further reinforcing its clinical value.

Innovative Cardiovascular Therapy Enhances Critical Care Management

RAPIBLYK’s mechanism of action allows for targeted beta-1 receptor blockade, reducing heart rate without significantly affecting other physiological parameters. This makes it particularly suitable for use in perioperative, postoperative, and intensive care settings, where careful cardiovascular management is essential. The drug is administered via intravenous infusion in monitored hospital environments, ensuring controlled delivery and immediate clinical oversight.

The approval also reflects broader trends in pharmaceutical innovation, where precision therapies and rapid-acting drugs are increasingly prioritized to improve outcomes in acute care scenarios. By expanding RAPIBLYK’s indication to pediatric patients, AOP Health is contributing to the advancement of specialized cardiovascular care and improved patient safety.

Strategic Impact on Pharma and Cardiovascular Innovation

The approval strengthens AOP Health’s presence in the United States and reinforces its position as a leader in cardiovascular and rare disease therapeutics. The company’s focus on developing science-driven, targeted therapies aligns with global healthcare priorities aimed at improving outcomes in complex and underserved conditions. This milestone also highlights the importance of clinical research, regulatory excellence, and innovation in expanding treatment options, particularly in pediatric populations where drug development has historically been limited.

The FDA approval of RAPIBLYK® for pediatric supraventricular tachycardia represents a significant breakthrough in cardiovascular care, offering a first-in-class, targeted treatment option for children and adolescents. With strong clinical evidence, rapid pharmacological action, and a favorable safety profile, RAPIBLYK is poised to become a critical tool in managing acute cardiac conditions in pediatric patients. This development underscores the vital role of pharmaceutical innovation and regulatory advancement in improving patient outcomes, particularly in high-risk and underserved populations.

Source: AOP Health press release